PDCD1 and neoplasm: Currently, there are three commonly used indicators for predicting the effectiveness of immunotherapy, that is, tumor mutation burden (TMB), microsatellite instability (MSI), and immune inhibitory genes (e.g., PD1/PD‐L1, CTLA‐4).